AMED - Amedisys, Inc.
NASDAQ
->
Healthcare
->
Medical Care Facilities
Baton Rouge,
United States
Type: Equity
AMED price evolution
AMED
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $138.86 | $94.02 | $111.16 | $69.1 |
| Short term investments | ||||
| Net receivables | $313.37 | $319.58 | $278.79 | $294.12 |
| Inventory | ||||
| Total current assets | $496.94 | $467.23 | $426.54 | $405.56 |
| Long term investments | ||||
| Property, plant & equipment | $130.78 | $127.47 | $121.54 | $118.56 |
| Goodwill & intangible assets | $1347.35 | $1348.31 | $1349.42 | $1344.61 |
| Total noncurrent assets | $1563.23 | $1560.19 | $1555.86 | $1541.4 |
| Total investments | ||||
| Total assets | $2060.17 | $2027.42 | $1982.4 | $1946.96 |
| Current liabilities | ||||
| Accounts payable | $28.24 | $34.55 | $38.56 | $40.02 |
| Deferred revenue | ||||
| Short long term debt | $62.6 | $61.48 | $57.25 | $52.41 |
| Total current liabilities | $473.72 | $468.12 | $462.4 | $353.05 |
| Long term debt | $424.61 | $428.73 | $429.53 | $433.03 |
| Total noncurrent liabilities | $466.67 | $465.78 | $459.24 | $460.56 |
| Total debt | $487.21 | $490.21 | $486.78 | $485.44 |
| Total liabilities | $940.39 | $933.9 | $921.64 | $813.61 |
| Shareholders' equity | ||||
| Retained earnings | $747.92 | $728.6 | $702.64 | $782.92 |
| Other shareholder equity | ||||
| Total shareholder equity | $1066.51 | $1039.91 | $1006.78 | $1079.12 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $138.86 | $54.13 | $45.77 | $83.36 |
| Short term investments | ||||
| Net receivables | $313.37 | $309.19 | $274.96 | $255.15 |
| Inventory | ||||
| Total current assets | $496.94 | $388.96 | $356.68 | $361.98 |
| Long term investments | ||||
| Property, plant & equipment | $130.78 | $118.88 | $119.69 | $117.16 |
| Goodwill & intangible assets | $1347.35 | $1388.57 | $1307.28 | $1006.87 |
| Total noncurrent assets | $1563.23 | $1587.28 | $1500.28 | $1205.21 |
| Total investments | ||||
| Total assets | $2060.17 | $1976.24 | $1856.97 | $1567.2 |
| Current liabilities | ||||
| Accounts payable | $28.24 | $43.73 | $38.22 | $42.67 |
| Deferred revenue | ||||
| Short long term debt | $62.6 | $49.02 | $44.23 | $40.54 |
| Total current liabilities | $473.72 | $355.53 | $374.28 | $456.34 |
| Long term debt | $424.61 | $419.42 | $501.38 | $266.5 |
| Total noncurrent liabilities | $466.67 | $514.14 | $506.36 | $300.12 |
| Total debt | $487.21 | $537.94 | $545.61 | $307.04 |
| Total liabilities | $940.39 | $924.67 | $880.64 | $756.46 |
| Shareholders' equity | ||||
| Retained earnings | $747.92 | $757.67 | $639.06 | $429.99 |
| Other shareholder equity | $1.43 | |||
| Total shareholder equity | $1066.51 | $1051.57 | $931.35 | $809.22 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $570.79 | $556.24 | $552.97 | $556.39 |
| Cost of revenue | $321.42 | $311.63 | $297.45 | $315.01 |
| Gross Profit | $249.37 | $244.61 | $255.51 | $241.38 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $135.12 | $129.08 | $125.5 | $126.34 |
| Total operating expenses | $215.36 | $202.4 | $217.72 | $199 |
| Operating income | $34.01 | $42.21 | $37.8 | $42.38 |
| Income from continuing operations | ||||
| EBIT | $37.73 | $46.31 | -$54.52 | $42.56 |
| Income tax expense | $10.18 | $12.33 | $18.25 | $9.8 |
| Interest expense | $8.23 | $8.02 | $7.5 | $7.52 |
| Net income | ||||
| Net income | $19.32 | $25.96 | -$80.28 | $25.25 |
| Income (for common shares) | $19.32 | $25.96 | -$80.28 | $25.25 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2236.38 | $2223.2 | $2214.11 | $2071.52 |
| Cost of revenue | $1245.51 | $1260.42 | $1233.36 | $1185.37 |
| Gross Profit | $990.87 | $962.77 | $980.76 | $886.15 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $516.05 | $508.79 | $474.72 | $449.45 |
| Total operating expenses | $834.48 | $782 | $728.84 | $666.88 |
| Operating income | $156.39 | $180.77 | $251.91 | $219.27 |
| Income from continuing operations | ||||
| EBIT | $72.09 | $183.38 | $288.66 | $220.28 |
| Income tax expense | $50.56 | $42.55 | $70.06 | $25.64 |
| Interest expense | $31.27 | $22.23 | $9.53 | $11.04 |
| Net income | ||||
| Net income | -$9.75 | $118.61 | $209.07 | $183.61 |
| Income (for common shares) | -$9.75 | $118.61 | $209.07 | $183.61 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $19.32 | $25.96 | -$80.28 | $25.25 |
| Operating activities | ||||
| Depreciation | $14.46 | $14.52 | $14.55 | $14.32 |
| Business acquisitions & disposals | $47.44 | |||
| Stock-based compensation | $9.4 | $7.24 | $9.11 | $3.27 |
| Total cash flows from operations | $60.31 | -$9.84 | $60.76 | $25.96 |
| Investing activities | ||||
| Capital expenditures | -$1.86 | -$0.98 | -$1.29 | -$1.35 |
| Investments | $0.15 | |||
| Total cash flows from investing | -$2.04 | -$1.05 | -$7.75 | $45.9 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.87 | $1.01 | $0.82 | |
| Net borrowings | -$8.9 | -$6.12 | -$5.68 | -$55.31 |
| Total cash flows from financing | -$13.43 | -$6.25 | -$10.95 | -$56.89 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $44.85 | -$17.14 | $42.06 | $14.97 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$9.75 | $118.61 | $209.07 | $183.61 |
| Operating activities | ||||
| Depreciation | $57.84 | $70.96 | $71.27 | $67.94 |
| Business acquisitions & disposals | $47.44 | -$71.95 | -$269.96 | -$298.96 |
| Stock-based compensation | $29.02 | $16.56 | $23.81 | $26.73 |
| Total cash flows from operations | $137.19 | $133.28 | $188.89 | $288.95 |
| Investing activities | ||||
| Capital expenditures | -$5.48 | -$6.1 | -$6.16 | -$5.25 |
| Investments | $0.15 | -$15.64 | -$5.2 | $17 |
| Total cash flows from investing | $35.06 | -$94.49 | -$281.61 | -$287.11 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.7 | -$11.2 | -$93.86 | $9.89 |
| Net borrowings | -$76.01 | -$13.3 | $227.38 | -$29.25 |
| Total cash flows from financing | -$87.52 | -$30.43 | $55.13 | -$14.98 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $84.73 | $8.36 | -$37.59 | -$13.13 |
News
|
Why Amedisys (AMED) is a Top Value Stock for the Long-Term
Zacks via Yahoo Finance
25 Mar 2024
|
|
How Amedisys (AMED) Stock Stands Out in a Strong Industry
Zacks via Yahoo Finance
20 Mar 2024
|
|
Amedisys' (AMED) Q4 Earnings Miss Estimates, Margins Up
Zacks via Yahoo Finance
23 Feb 2024
|
|
Option Care Health, Inc. (NASDAQ:OPCH) Q3 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance
26 Oct 2023
|
|
Amedisys' (AMED) Q3 Earnings Miss Estimates, Margins Up
Zacks via Yahoo Finance
26 Oct 2023
|
|
Henry Schein (HSIC) Acquires Majority Stake in Shield Healthcare
Zacks via Yahoo Finance
24 Oct 2023
|
|
Stock Analysts’ New Coverage for October 23rd (AACG, AAME, ADXS, AEY, AKTX, AMED, AP, APWC, ARTW,...
ETF DAILY NEWS
23 Oct 2023
|
|
Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?
Zacks via Yahoo Finance
18 Oct 2023
|
|
Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Dip
Zacks via Yahoo Finance
28 Jul 2023
|
|
Company News for Jul 27, 2023
Zacks via Yahoo Finance
27 Jul 2023
|
Fundamentals
| Market cap | $2.97B |
|---|---|
| Enterprise value | $3.32B |
| Shares outstanding | 32.67M |
| Revenue | $2.24B |
|---|---|
| EBITDA | $129.93M |
| EBIT | $72.09M |
| Net Income | -$9.75M |
| Revenue Q/Q | 1.55% |
| Revenue Y/Y | 0.59% |
| P/E ratio | -305.16 |
|---|---|
| EV/Sales | 1.49 |
| EV/EBITDA | 25.57 |
| EV/EBIT | 46.09 |
| P/S ratio | 1.33 |
| P/B ratio | 2.79 |
| Book/Share | 32.65 |
| Cash/Share | 4.25 |
| EPS | -$0.30 |
|---|---|
| ROA | -0.49% |
| ROE | -0.93% |
| Debt/Equity | 0.88 |
|---|---|
| Net debt/EBITDA | 6.17 |
| Current ratio | 1.05 |
| Quick ratio | 1.05 |